Metabolic Imaging of Advanced Basal Cell Carcinoma Treated with Sonidegib: A Retrospective Case Series Study.

ABSTRACT: Background: Positron emission tomography/computed tomography (PET/CT) with ¹⁸F-fluorodeoxyglucose (¹⁸F-FDG) is a firmly established tool in oncology and is gaining importance in dermato-oncology. However, its use in advanced basal cell carcinoma (BCC) is limited, with only a few case reports and a single study focused on vismodegib. This study evaluates the role of ¹⁸F-FDG PET/CT in advanced BCC treated with sonidegib. Methods: We retrospectively assessed the clinical data of patients with advanced BCC who underwent ¹⁸F-FDG PET/CT between January 2022 and January 2024. Inclusion criteria included histologically confirmed BCC, FDG-avid lesions on baseline PET/CT, and a minimum follow-up of 6 months. Metabolic response was assessed us

SUBMITTER: Proietti I 

PROVIDER: S-EPMC11396429 | biostudies-literature | 2024 Aug

REPOSITORIES: biostudies-literature